Biogen/Ionis’ Tofersen Wins Accelerated Approval In ALS Subgroup – A Significant But Narrow Precedent

 
• By Sue Sutter
Footsteps on beach
Other ALS drug developers will look to follow Biogen/Ionis' lead in using reduction in neurofilament concentration as the basis for accelerated approval. • Source: Shutterstock

More from Approvals

More from Product Reviews